Orthogonal systems to cell-based assays are a key requirement in EMA/FDA guidelines for potency estimations and require cross-validation with complementary approaches to prove and strengthen the reliability of results.
In this application note published in collaboration with IBR Inc., you will learn:
- Why Alpha technology represents an ideal cell-free orthogonal system for potency assays
- How AlphaLISA® assays can be used to determine Bevacizumab/VEGF165 potency
- An example of how to run an AlphaLISA potency assay and the type of data that can be generated
- Why it is suitable for assessing lot-to-lot consistency and equivalence of Bevacizumab and biosimilars
